We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kuala Innov | KUL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.25 |
| Top Posts |
|---|
Posted at 22/11/2015 18:34 by keya5000 It is very interesting to see that Coinsilium. will be IPO at a £6m valuation which is 50% more than KUL with what across the board is a very similar set of investments and its on ISDX.That's roughly 5x value of its actual investments against its mcap. KUL could have a further £1m+ (£655k already raised and a further placing imminent on the same terms) invested by mid December and have substantially higher stakes in all the projects that they share plus KUL have Mellon/Dattell at the helm. I would say a mcap of £15m for KUL would be about par with the current only market comparable in coinsilium and that's being kind. |
Posted at 13/11/2015 15:22 by doodlebug4 "The Stigologist 13 Nov'15 - 14:52 - 434 of 435 0 0doodlemug has been claiming KUL is the only company investing in blockchain wrong/lie" Actually the above post is a lie. I have never claimed that KUL is the only company investing in the blockchain and I'm very well aware that there is competition in the market. Stigologist is the one who needs to get his facts right. |
Posted at 09/11/2015 14:12 by flashheart Sorry for slightly off topic but fellow Kuala club members may also be tempted by VELA. A similar VCT/Enterprise incubator to KUL which has also just taken a stake in block chain technology if anyone wants further exposure to this area. KUL seems to be taking a breather before the next leg up I think. |
Posted at 08/11/2015 09:15 by keya5000 Glad he's focussing in the US for the investments, just don't think the UK market place is sharp enough to develop these type of companies (with the odd exception).The interview he did with Money Week (think that was the name with the video) leads me o believe he will be concentrating on embryonic US companies. Given the fast forward book and strategy was started in 2014 (possibly way before) you would have thought he (Mellon) would have been creating the contacts and talking about the deals throughout the previous eighteen months. No doubt he owns several more shares in early stage companies on a private basis and I reckon there are likely already connected entities/stakes that will be reversed onto this when the name change takes place. All looking good and I reckon any raise they do won't be in the millions and won't be detrimental to the prevailing share price at the time, in fact quite the opposite. At the time of the last fund raising the direction and the driving forces behind such had not been known, quite easy to see now what's happening here and say if he raises £500k at 10% discount to the share price you know that cash will soon be deployed into something likely very worthwhile. So whilst I accept a fund raise at some point (it is inevitable) the amounts will I expect be small and only raised when specifically needed. It is also worth considering that he may in effect create a 'directors buy' by exchanging already owned assets with KUL shares. I would expect a none damaging (I.e. Not like YA) conv.loan type facility could be arranged given the connections. Yes all these options lead to re dilution but we start with such a small number in issue the key to me is to who and how the shares KUL will need to issue are issued to. I don't expect them to go to 'flippers' and create an ever increasing free float of moving ever changing stock. |
Posted at 06/11/2015 10:04 by wolf9 the stake in intensity alone could account for 3 or 4p of the current kul share price imo after that great update from intensity. the mc of kul is still under £5M and with the prospects of the other investments looking so promising i am hoping to see a good appreciation in the mc of kul. gla |
Posted at 02/11/2015 17:34 by flashheart I see both KUL and TERN (sorry to disagree keya and Hydrus) as exciting opportunities here with the investments they have. Would like to see KUL up their stake in Factom significantly though if I'm honest as I see this particularly as a KUL 'game changer'. |
Posted at 18/10/2015 20:36 by hedgehog 100 Thanks DB - excellent work!Remember your near namesake (abbreviated) DBC though!! KUL's 7th. September acquisition of a stake in DBC was acquired for shares from Messrs. Dattels & Mellon (at a deemed value of 5p per KUL share), and was therefore in effect director share buying in KUL by them. 07/09/2015 07:00 UK Regulatory (RNS & others) Kuala Innovations Limited Acquisition "... The Board of Kuala Innovations Limited ("Kuala" or the "Company") is pleased to announce the acquisition of a 4.9 per cent. interest in the issued shares of UK incorporated private company The Diabetic Boot Company Limited ("DBC"). DBC is a private single product medical device company based near Oxford, in the UK. DBC is focussed on the treatment of diabetic foot ulcers ("DFUs"), which are a comorbidity of diabetes mellitus. The treatment of DFUs represents a significant commercial opportunity with the current standard of care and alternative therapies lacking efficacy. DBC's lead product is the PulseFlow(R) which combines intermittent plantar compression with the current standard of care for the treatment of DFUs called offloading. Technology created by DBC in relation to the PulseFlow is currently the subject of a number of granted patents in key jurisdictions, with further patents submitted. Intermittent plantar compression as a mechanism of action has been shown in independent clinical studies to produce statistically significant improvements over placebo in wound closure. ..." "With lead investment from ‘master investor’ Jim Mellon, The Diabetic Boot Company (now Pulse Flow Technologies) successfully raised £1,764,493 to help support the company’s product development and rollout. The Story Every 20 seconds, someone in the world loses a limb to diabetes. Studies show that 50% of those people die within 2 years. Between 2010 - 2011, the NHS spent up to £662 million on ulceration and amputation. The International Diabetes Federation forecasts that the number of diabetics worldwide is likely to reach 552 million by 2030. CEO Les Lindsay, formerly VP of KCI Medical, founded The Diabetic Boot Company (now known as Pulseflow) to solve this problem using innovative biotechnology. The result was 'pulseflow DF' - a patented and clinically proven design capable of healing foot ulcers caused by diabetes within 12 weeks. What’s more, the Armstrong research study showed that the intermittent plantar compression feature utilised in the pulseflow DF resulted in 100% of wounds healed within 12 weeks for compliant patients. Where are they now? The Diabetic Boot Company has received numerous awards, including ‘Start Up Business’ Winner in the 2014 SEHTA Healthcare Business Awards. It was also a runner up for ‘Start Up Business’ in the 2015 Medilink UK Awards, and received a funding grant from Technology Strategy Board. The company was also discussed in the press, most notably in an article by The Telegraph. Investment in this round was led by Jim Mellon, whose most notable investment was UraMin Inc which listed on AIM in 2005 and sold to Areva for £1.6 billion in 2007. You can read more about Jim Mellon in This Is Money, The Telegraph, The FT, FT Advisor and The Sunday Times." |
Posted at 13/10/2015 16:33 by hedgehog 100 06/10/2015 08:03 UKREG Kuala Innovations Limited Investment in Intensity Therapeutics Inc" ... Intensity Therapeutics is currently under-going a "Series A Fundraising" to raise approximately US$5 million. It is anticipated that, on completion of the Series A Funding round Intensity Therapeutics will have a post-money market capitalisation of approximately US$19.0 million (based on US$2.00 per share). Intensity Therapeutics, Inc. Intensity Therapeutics is a biotechnology company focused on cancer immunotherapy. Intensity's novel technology has the potential to transform the lives of patients with cancer. ... " Compare Intensity Therapeutics to cancer biotech Tizania Life Sciences (TILS) ... a former shell like Kuala. TILS was a RTO (reverse takeover) in May of last year, accompanied by a placing at just 12p, since when it has reached 250p: "Tiziana shares soar By Harriet Russell, 05 October 2015 Tiziana Life Sciences(TILS) only floated on the London market a year and a half ago, but since then the stock has rocketed from a listing price of 12p, reaching a peak of 250p in August. In tandem with the European Cancer Stem Cell Research Institute in Cardiff, Wales, the group has identified the BCL3 gene as crucial in halting the spread of metastatic cancers to other parts of the body. It is now developing drugs to stop the disease being life-threatening. So far this year, the group has signed two significant licensing deals. The first, with the Italian Nerviano Medical Centre, will see Tiziana initiate a third-phase clinical trial of milciclib - a potential treatment for a rare type of thymus gland cancer - in 2016. The second will allow Tiziana to use the University of Cardiff's anti-cancer stem-cell technology in a research project for OH14, a potential treatment which could instruct the human body to kill off cancerous cells. Outside of oncology, the group is also working on a potential drug licensed from Swiss biotech outfit Novimmune. The treatment could work across a range of autoimmune and inflammatory diseases such as multiple sclerosis, type-1 diabetes and arthritis. Clinical development plans have yet to be finalised. TIZIANA LIFE SCIENCES (TILS) ORD PRICE: 193p MARKET VALUE: £178m TOUCH: 185-200p 12-MONTH HIGH: 250p LOW: 42p DIVIDEND YIELD: nil PE RATIO: na NET ASSET VALUE: 7p NET CASH: £7m Half-year to 30 June Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 0.0 -1.6 -4.8 nil 2015 0.0 -4.1 -4.6 nil % change - - - - Ex-div: na Payment: na IC VIEW: A placing in March netted the group an additional £2.7m, but doubts persist over how long the cash will last. Investors in cancer research have to be prepared for regular equity fundraisings. The profit pay-off could be huge if these drugs prove effective, but it's a long-term gamble. Hold. Last IC view: Hold, 141p, 9 June 2015" |
Posted at 09/10/2015 16:01 by hedgehog 100 KUL's 7th. September acquisition of a stake in DBC was acquired for shares from Messrs. Dattels & Mellon, at a deemed value of 5p per KUL share, and was therefore in effect director share buying in KUL by them.KUL also raised £200K. in placings in September at a price of 5p (2 x £100K.). It's nice to be able to buy in at the same price as placees, and even nicer if directors have been increasing their stake at that same price. |
Posted at 07/10/2015 17:52 by hedgehog 100 Mike,If KUL do invest in MED it will clearly be their first investment in a listed company. KUL is currently a superb way to gain exposure to pre-IPO situations that retails investors are usually excluded from. And all of its investments have the potential to come to market in the near-term, at higher valuations, and then to grow rapidly from there. Indeed I believe that if KUL's portfolio fulfils its promise, then KUL could ten to twenty bag over the next two to three years, i.e. to £1 per share. So an investor with a nice holding here could therefore potentially make a portfolio-transformi |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
